Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA LLC
Published Date: 2/4/2026
Notice
Summary
Sterling Pharma USA LLC wants to become a big-time maker of some powerful controlled substances like psilocybin and DMT for research and early drug testing. People already registered or interested can share their thoughts or ask for a hearing by April 6, 2026. This move could speed up new medicine studies, but only for research—not for regular sales.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New Bulk Supplier for Schedule I Research
On January 9, 2026, Sterling Pharma USA LLC applied to be registered as a bulk manufacturer of the Schedule I substances tetrahydrocannabinols (code 7370), 5‑methoxy‑N‑N‑dimethyltryptamine (code 7431), dimethyltryptamine (code 7435), psilocybin (code 7437), and psilocyn (code 7438). If registered, the company may manufacture these substances in bulk to support its internal research and to sell to customers for pre‑clinical trial studies; no other activities for these drug codes would be authorized under the registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-02229, Notice of Reinstatement of the Gasoline Volatility Waiver for Ohio
The EPA just gave Ohio the green light to bring back a special rule that lets summer gasoline with 10% ethanol be a bit more volatile (1 psi higher). This change helps Ohio gas stations and drivers by allowing easier fuel blends starting February 4, 2026, and could save money on fuel costs. Ohio folks and fuel sellers should get ready for this smoother, more flexible gas rule making summer driving a little easier!
Next: 2026-02231, FAA Aircraft Noise Complaint and Inquiry System (Noise Portal); Correction
The FAA fixed a small but important mistake in their January 20, 2026 notice about the Aircraft Noise Complaint and Inquiry System (Noise Portal). They added the missing docket number so everyone can find the right info easily. This correction doesn’t cost money or change any deadlines but helps keep things clear for anyone affected, like travelers and local communities near airports.